Thoracic Imaging

Suspected NSCLC Recurrence: Which Imaging Study Should You Order First?

·
Suspected NSCLC Recurrence: Which Imaging Study Should You Order First?

A 68-year-old patient with a history of surgically resected stage II non–small-cell lung cancer (NSCLC) presents to your clinic 18 months post-treatment. He reports two weeks of persistent, dull headaches and a new, subtle imbalance when walking. His physical exam is largely non-focal, but the new neurological symptoms in the context of his cancer history raise immediate concern for intracranial recurrence. You need to decide on the most appropriate imaging study to evaluate for brain metastases, a critical step that will dictate the next phase of his management. For this specific clinical question, the American College of Radiology (ACR) rates `MRI head without and with IV contrast` as Usually appropriate.

Who Fits This Clinical Scenario?

This guidance applies specifically to adult patients who have completed definitive treatment for stage I, II, or III non–small-cell lung cancer and now present with new or worsening signs or symptoms suspicious for cancer recurrence or progression. The “suspicion” is key—it is driven by a change in clinical status, such as new cough, chest pain, weight loss, bone pain, or, as in our vignette, neurological symptoms.

This workflow is distinct from other common clinical situations. It is crucial to differentiate this scenario from:

  • Routine surveillance in an asymptomatic patient: A patient with a history of treated NSCLC who feels well and is undergoing scheduled follow-up imaging falls under a different ACR variant. That scenario focuses on routine, scheduled imaging to detect recurrence before symptoms develop. This article is for a patient with an active clinical problem.
  • Suspected recurrence in small-cell lung cancer (SCLC): SCLC has a distinct natural history, a higher propensity for early and widespread metastasis (including to the brain), and different treatment paradigms. Imaging strategies for suspected SCLC recurrence are addressed separately.
  • Initial staging of a new lung cancer diagnosis: The imaging workup for a newly discovered lung mass is focused on initial staging (TNM classification) and is not covered by this post-treatment surveillance guidance.

What Diagnoses Are You Working Up in This Scenario?

When a patient with treated NSCLC presents with new symptoms, the differential diagnosis is centered on distinguishing cancer recurrence from other etiologies. The choice of imaging is designed to evaluate these possibilities, particularly the most life-altering ones.

Distant Metastasis: This is the primary concern, especially with symptoms pointing to a specific organ system. For patients with neurological symptoms, brain metastases are the most common cause. NSCLC, particularly adenocarcinoma, has a known predilection for spreading to the brain. Identifying intracranial disease is critical as it profoundly impacts prognosis and treatment, often requiring targeted therapies like stereotactic radiosurgery.

Locoregional Recurrence: The cancer may have returned at or near the original tumor site, in the surgical bed, or in nearby lymph nodes. Symptoms might include a persistent cough, shortness of breath, or chest wall pain. This requires dedicated imaging of the thorax.

Post-Treatment Changes: Not all new findings on imaging represent recurrence. Radiation pneumonitis, fibrosis, or post-surgical scarring can mimic or obscure recurrent tumors. Differentiating these benign changes from active malignancy is a central challenge in post-treatment surveillance and often requires advanced imaging techniques.

Second Primary Malignancy: Patients with a history of lung cancer are at an increased risk for developing a new, second primary cancer, either in the lung or elsewhere. This is a less common, but important, consideration in the differential.

Non-Malignant Conditions: The patient’s symptoms could be unrelated to their cancer history. For example, new headaches could be from tension, migraine, or a cerebrovascular event. A new cough could be infectious. Imaging helps rule out recurrence so these other conditions can be confidently diagnosed and managed.

Why MRI Head Without and With IV Contrast Is a Recommended Study for This Presentation

For a patient with treated NSCLC presenting with neurological symptoms, evaluating for intracranial metastasis is the immediate priority. While several imaging studies are rated Usually appropriate for the broad workup of suspected recurrence, `MRI head without and with IV contrast` is the superior and recommended modality for specifically assessing the brain.

The ACR rates MRI head without and with IV contrast as Usually appropriate due to its unmatched soft-tissue resolution. It can detect small metastatic deposits, leptomeningeal disease, and subtle edema that would be missed by other modalities. The addition of intravenous gadolinium-based contrast is essential; metastatic lesions are typically vascular and will enhance, making them conspicuous against the normal brain parenchyma. An MRI without contrast is significantly less sensitive and is rated lower (May be appropriate).

Other highly-rated studies serve different, complementary purposes in the overall workup:

  • FDG-PET/CT skull base to mid-thigh: Also rated Usually appropriate, this is an excellent tool for systemic staging and detecting recurrence anywhere in the body. It is particularly valuable for differentiating post-treatment scarring from active tumor in the chest. However, its spatial resolution in the brain is inferior to MRI, and the high baseline metabolic activity of the brain can obscure small metastases.
  • CT chest with or without IV contrast: Rated Usually appropriate, this is the workhorse for evaluating locoregional recurrence in the lungs, mediastinum, and pleura. It is fast and widely available. However, for evaluating the brain, a dedicated `CT head with IV contrast` is only rated May be appropriate because it has lower sensitivity for small metastases compared to MRI.

The choice between these studies often depends on the presenting symptoms. If neurological symptoms are present, MRI of the head is the logical first step. If symptoms are thoracic (cough, chest pain) or constitutional (weight loss), a CT chest or a whole-body PET/CT may be more appropriate to start. From a safety perspective, MRI avoids ionizing radiation (0 mSv), a relevant consideration in patients who have undergone multiple prior imaging studies and radiation therapy.

What’s Next After MRI Head Without and With IV Contrast? Downstream Workflow

The results of the brain MRI will guide a critical decision tree for patient management. The downstream workflow is not just about the report, but about integrating the findings with the patient’s overall clinical picture.

If the MRI is positive for brain metastases: The immediate next step is a referral to a neuro-oncology multidisciplinary team, including neurosurgery and radiation oncology. Management may involve stereotactic radiosurgery (SRS) for a limited number of lesions, whole-brain radiation therapy (WBRT) for more extensive disease, or systemic therapy that has CNS penetration. The presence of brain metastases also necessitates systemic restaging, often with an `FDG-PET/CT skull base to mid-thigh` (if not already performed), to determine the full extent of disease progression.

If the MRI is negative: A negative brain MRI effectively rules out intracranial metastasis as the cause of the patient’s symptoms. However, the workup is not complete. The focus must then shift to finding a locoregional or other distant extracranial source of recurrence. The next logical step is to order a `CT chest with IV contrast` to evaluate the thorax or an `FDG-PET/CT` to assess the entire body for metabolically active disease. This addresses the possibility that the patient’s symptoms are from a paraneoplastic syndrome driven by a recurrence elsewhere.

If the MRI is indeterminate: Findings such as a solitary, small enhancing lesion can be ambiguous. The differential includes a small metastasis, a primary brain tumor, or an infectious or inflammatory process. In this case, a short-interval follow-up MRI in 4-6 weeks can assess for growth. Advanced MRI techniques like perfusion imaging or spectroscopy may help, and in some cases, a stereotactic biopsy may be required for a definitive diagnosis.

Pitfalls to Avoid (and When to Get Help)

Navigating the workup for suspected NSCLC recurrence requires careful attention to detail to avoid common missteps.

  • Substituting CT for MRI: Do not order a CT head as the primary study for suspected brain metastases unless MRI is contraindicated (e.g., incompatible pacemaker). The lower sensitivity of CT can lead to a false-negative result, delaying a critical diagnosis.
  • Omitting IV Contrast: A non-contrast MRI of the brain is inadequate for this indication. Metastases may be isointense to brain tissue and only become visible after the administration of gadolinium. Always specify “without and with IV contrast.”
  • Attributing all changes to recurrence: Be aware of treatment-related mimics. Radiation necrosis can appear very similar to a recurrent tumor on imaging. This often requires advanced imaging or multidisciplinary tumor board discussion to resolve.
  • Stopping the workup too soon: A negative brain MRI in a symptomatic patient is reassuring but does not end the investigation. You must proceed with imaging the chest and potentially the rest of the body to find the source of the suspected recurrence.

If imaging reveals complex or widespread metastatic disease, especially involving the central nervous system, immediate escalation to a multidisciplinary tumor board is essential for coordinating care between medical oncology, radiation oncology, and neurosurgery.

Related ACR Topics and Tools

For a comprehensive overview of imaging across all post-treatment lung cancer scenarios, please consult the parent topic article. For additional decision support and technical details on the studies discussed, the following GigHz resources are available.

Frequently Asked Questions

Why not just order a whole-body PET/CT to begin with, since it covers the brain?

While FDG-PET/CT is rated ‘Usually appropriate’ for systemic evaluation, it has limitations in the brain. The brain’s high baseline glucose metabolism can obscure small metastatic lesions, and the spatial resolution of PET is lower than MRI. For a patient with specific neurological symptoms, a dedicated brain MRI is far more sensitive for detecting intracranial disease.

What should I order if my patient has a contraindication to MRI, like a non-compatible pacemaker?

In cases where MRI is contraindicated, the next best imaging study is a ‘CT head with IV contrast.’ While less sensitive than MRI, it is rated as ‘May be appropriate’ by the ACR and is the standard alternative for identifying larger lesions, hemorrhage, or mass effect.

Is a non-contrast MRI of the head ever sufficient in this scenario?

No, a non-contrast MRI is generally insufficient. Many brain metastases are only clearly visualized after the administration of gadolinium-based contrast agents, which cause the lesions to enhance. The ACR rates ‘MRI head without IV contrast’ as only ‘May be appropriate,’ a tier below the study with contrast, reflecting its lower diagnostic yield.

My patient has no neurological symptoms, but their tumor marker (e.g., CEA) is rising. Should I still order a brain MRI?

In an asymptomatic patient with only biochemical evidence of recurrence, the goal is to localize the disease anywhere in the body. An ‘FDG-PET/CT skull base to mid-thigh’ is often the preferred initial test in this situation, as it provides a comprehensive systemic survey. A brain MRI would typically be reserved for if the PET/CT is negative but suspicion remains high, or if the patient later develops neurological symptoms.

How does this workup differ from surveillance for small-cell lung cancer (SCLC)?

SCLC has a much higher rate of early brain metastasis compared to NSCLC. Because of this, brain imaging is a more routine part of both initial staging and surveillance. Furthermore, prophylactic cranial irradiation (PCI) is sometimes used in SCLC, which can cause post-treatment changes on imaging that complicate the interpretation of surveillance scans. The clinical context and pre-test probability are significantly different.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026